Also, a phase II study of targeting CD28 in multiple myeloma with abatacept (CTLA4-Ig) determine the therapeutic efficacy to overcome resistance to chemotherapy (NCT03457142). The gene discussed is CTLA4; the disease is plasma cell myeloma.